A Revolutionary Advancement in Early Skin Cancer Detection
Early Detection Save Lives
Jointly developed by the BC Cancer Agency and the University of British
Columbia, and refined and tested at the Skin Care Centre at Vancouver
General Hospital, this patent protected technology has already been used
in a human clinical study spanning six years on approximately 1,000
lesions. Preliminary results published in 2008 showed the Verisante Aura™
found every case of melanoma in 274 lesions flagged for biopsy.
Verisante Aura™ will help to automate the current process of diagnosis,
allowing rapid scanning of the 20 – 40 skin lesions on “at risk” individuals.
No longer will patients need to suffer through long wait times to see a dermatologist,
as scans may be accomplished quickly by trained technicians
or assistants. Verisante Aura™ will greatly aid healthcare professionals,
delivering significant clinical impact through improved patient outcomes
and reduced wait times; while also decreasing healthcare costs by detecting
skin cancer in its early, most easily treatable stages.
The Verisante product development team is led by award-winning pioneers
in the field of cancer imaging. In addition, the Company is proud to have
world renowned experts in early cancer detection involved with our
technical and medical team.
The Facts on Skin Cancer
• Skin cancer is the most common form of cancer, and most rapidly increasing
• Every hour, one person in the United
States dies of melanoma
• 50% of people over the age of 65 in the
US will be affected by skin cancer
• Survival rate for patients where the disease is detected early is 98%
• Survival rate of patients with advanced stage skin cancer is 15%
• The treatment of advanced stage melanoma costs 2200% more than early stage melanoma
• The annual treatment cost of treating skin cancer in the United States is estimated at USD $2.5 billion
Investment Highlights
• Revolutionary technology
• Imaging device for the safe and early detection of skin cancer
• Patent protected platform technology
• Extensible to several other forms of cancer
• Clear regulatory pathway that will result in significant early revenue
• Recurring revenue model
• Strategic alliances with leading institutions
• World class scientific capability
• Project management lead by experienced, award-winning pioneers
• Medical and technical team lead by renowned experts
• Highly qualified management
• Strong, independent Board
Company Profile
Verisante is a medical device company committed to commercializing Verisante AuraTM for skin cancer detection in 2011. The Company develops innovative systems for the early detection of cancer. Verisante AuraTM and Verisante CoreTM (for lung, colon and cervical cancer detection) utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device.
This exclusive platform technology allows Verisante to develop compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.
